Skip to main content

Advertisement

Table 2 Summary of ongoing clinical trials with ICI in solid tumor with brain metastasesa

From: Immunotherapy of brain metastases: breaking a “dogma”

Clinical trial identifier Trial Name Phase Status
NCT03175432 Study of Bevacizumab in Combination With Atezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) II Recruiting
NCT02460068 A Study of Fotemustine (FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2) III Recruiting
NCT03340129 Anti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study) (ABC-X) II Not yet recruiting
NCT03728465 Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma II Recruiting
NCT02681549 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer II Recruiting
NCT02858869 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases I Recruiting
NCT03563729 Melanoma Metastasized to the Brain and Steroids (MEMBRAINS) II Recruiting
NCT03873818 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain II Recruiting
NCT02130466 A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (patients with inactive brain metastases eligible) I/II Recruiting
NCT02696993 Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer I/II Recruiting
NCT02978404 Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases II Recruiting
NCT02886585 Pembrolizumab In Central Nervous System Metastases II Recruiting
NCT03867175 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer III Not yet Recruiting
NCT03719768 Avelumab With Radiotherapy in Patients With Leptomeningeal Disease I Recruiting
NCT03325166 Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases II Recruiting
NCT02648477 Pembrolizumab and doxorubicin hydrochloride or anti-estrogen therapy in treating patients with triple-negative or hormone receptor-positive metastatic breast cancer II Recruiting
NCT03483012 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis II Recruiting
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (SRS) Of Selected Brain Metastases In Breast Cancer Patients I/II Recruiting
NCT03526900 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis (ATEZO-BRAIN) II Recruiting
  1. a as of Sep 4, 2019. Source: clinicaltrials.gov
  2. ABC Australian Brain Collaboration, SRS/SBRT stereotactic radiosurgery